Publications by authors named "P Lundmo"
Objective: The Early Prostate Cancer (EPC) programme is evaluating the efficacy and tolerability of bicalutamide following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with localized (T1-2, N0/Nx) or locally advanced (T3-4, any N; or any T, N + ) non-metastatic prostate cancer. Herein we report the latest findings after a median follow-up period of 7.1 years from the Scandinavian Prostate Cancer Group (SPCG)-6 study, one of three trials in the EPC programme.
View Article and Find Full Text PDFArticle Synopsis
- This study assessed the impact of adding 150 mg of bicalutamide to standard treatments for localized or locally advanced prostate cancer, focusing on two main outcomes: progression-free survival (PFS) and overall survival.
- A total of 1,218 men were randomized to receive either bicalutamide or a placebo alongside standard care, showing that those with locally advanced disease had improved survival with bicalutamide, while those with localized disease experienced decreased survival.
- Bicalutamide significantly enhanced PFS, reducing disease progression risk by 43%, particularly benefiting patients with locally advanced cancer, indicating the need to consider tumor burden when evaluating treatment options for untreated patients.
Objectives: To report an exploratory subgroup analysis assessing the extent to which the overall benefit found in the Early Prostate Cancer program is dependent on lymph node status at randomization. The program is ongoing, and the overall survival data are immature. The first combined analysis of the bicalutamide (Casodex) Early Prostate Cancer program at 3 years' median follow-up showed that bicalutamide, 150 mg once daily, plus standard care (radical prostatectomy, radiotherapy, or watchful waiting), significantly reduced the risk of objective progression and prostate-specific antigen (PSA) doubling in patients with localized/locally advanced prostate cancer.
View Article and Find Full Text PDFObjectives: To examine the development of antiandrogen-induced gynecomastia and breast tenderness in the first 253 patients in a randomized Scandinavian trial (SPCG-7/SFUO-3) with a 12-month complete follow-up evaluation performed by both doctors and patients.
Methods: In this study, the treating doctor and patient decided whether prophylactic irradiation (RT) of the breast should be given to prevent antiandrogen-induced gynecomastia. At each visit, the doctor evaluated the occurrence of gynecomastia and breast tenderness.